Open AccessLeukoreduced blood components: Advantages and strategies for its implementation in developing countries
Author(s) -
Ratti Ram Sharma,
Neelam Marwaha
Publication year - 2010
Publication title -
asian journal of transfusion science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.262
H-Index - 22
eISSN - 1998-3565
pISSN - 0973-6247
DOI - 10.4103/0973-6247.59384
Subject(s) - medicine , apheresis , intensive care medicine , blood management , scope (computer science) , blood transfusion , human leukocyte antigen , platelet , immunology , antigen , computer science , programming language
Removal of leucocytes from various blood products has been shown to minimize Febrile nonhemolytic transfusion reactions, HLA alloimmunization, platelet refractoriness in multitransfused patients and prevention of transmission of leukotropic viruses such as EBV and CMV. Rapidly growing size of hemato-oncological patients in our country requiring multiple transfusion of blood and components during the course of their management pose a great challenge to transfusion services to provide them red cell and platelet antigen matched products in alloimmunized subjects. Thus removal of leucocytes below a certain threshold, </= 5 x 10(6) in a blood component certainly helps in prevention of alloimmunization and associated risks in these patients. Currently the best Leucoreduction can be achieved with the help of 3rd and 4th generation leukofilters, both in laboratory and patient bed side, and state of the art apheresis devices. The present article briefly reviews the current literature for pros and cons of leucofilteration and its scope of implementation in the cost constrained settings.